Indiana University
MAPS & DIRECTIONS Maps FIND PEOPLE Find People

Christian Sarkine Autism Treatment Center Active Research Projects

OUR RESEARCH PHONE NUMBER HAS CHANGED. PLEASE CONTACT 317-944-9766 FOR ALL RESEARCH OPPORTUNITIES.

Autism Spectrum Disorders 

 

AUTISM RESEARCH STUDY

The Section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a study designed to study the effects of acamprosate in individuals with autism.  Participants must be children between the ages of 5 and 17 with autism.  Participants will receive study medication at no charge. 

For additional information about study requirements and study procedures, please call one of Dr. Craig Erickson’s research staff at (317) 948-9766 or at kidpsych@iupui.edu.

PERVASIVE DEVELOPMENTAL DISORDERS RESEARCH STUDY

The section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a study designed to study the effects of mirtazapine in children with Pervasive Developmental Disorders (PDD's). Participants must be children between the ages of 5 and 17 with autistic disorder, Asperger's disorder or PDD as well as difficulties with anxiety. Participants must have no medical illness and not have had a previous adequate trial of mirtazapine.

Participants will receive study medication at no charge. For additional information about study requirements and study procedures, please contact Dr. Christopher McDougle's study staff at (317) 948-9766 or kidpsych@iupui.edu.

AUTISM SPECTRUM DISORDER: ASSESSING NEEDS FOR INFORMATION AND TRAINING IN INDIANA

We would like your input! Dr. Swiezy (HANDS Program, Christian Sarkine Autism Treatment Center) is conducting a needs assessment to evaluate the particular interests and needs for training topices and formats by parents/caregivers, school personnel, medical professionals, and service providers who interact with individuals with an autism spectrum disorder.

The survey is available online at http://handsinautism.org/surveys.html and will take 10 to 15 minutes to fill out. All the responses are anonymous.

AUTISM RESEARCH STUDY

The Christian Sarkine Autism Treatment Center at IU School of Medicine Department of Psychiatry is conducting a 24-week parent training research study. Children must be between the ages of 3 and 7 with Autism, Asperger's Disorder, or PDD-NOS. Participation requirements, benefits, and risks will be disclosed prior to study enrollment.

For additional information about study requirements and study procedures, please contact us at (317) 948-9766 or kidpsych@iupui.edu.

A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF D-CYCLOSERINE FOR THE ENHANCEMENT OF SOCIAL SKILLS TRAINING IN PERVASIVE DEVELOPMENTAL DISORDERS

The Christian Sarkine Autism Treatment Center at Riley Hospital for Children is conducting a Research Study for 5-11 year old children who have Autism Spectrum Disorders. If your 5-11 year old child has Autism, Asperger's or PDD NOS, he or she may qualify for a research study involving an investigational study medication, social skills training, and clinic visits with a child psychiatrist and qualified research staff.

This 14-week study, conducted by David Posey M.D., M.S of the Indiana University School of Medicine at the Christian Sarkine Autism Treatment Center, Riley Hospital for Children, is looking at this investigational study medication as a way of enhancing the effectiveness of social skills development.

Benefits of the study include: assessments, social skills training and study medication provided at no charge. Risks of the study include: being assigned to placebo or having side effects from the study medication, or the inconvenience of attending study visits. Participation requirements plus additional benefits and risks involved in this study will be disclosed prior to study enrollment.

If you are interested in participating or would like more information, please call the Christian Sarkine Autism Treatment Center at (317) 948-9766 or email: kidpsych@iupui.edu

PERVASIVE DEVELOPMENT DISORDERS RESEARCH STUDY

The Section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a study designed to study the effects of aripiprozale in children with Pervasive Developmental Disorders (PDD's). Participants must be children between the ages of 5 and 17 with Pervasive Developmental Disorder (PDD) as well as behavioral difficulties such as irritability, tantrums, aggression and self-injurious behavior. Participants must have no medical illness and not have had a previous adequate trial of aripiprozale. Participants will receive study medication at no charge. For additional information about study requirements and study procedures, please contact us at (317) 948-9766 or kidpsych@iupui.edu

For more information about this study, click here.

NOVEL PHARMACOLOGICAL STRATEGIES  IN AUTISM

The Christian Sarkine Autism Treatment Center at Riley Hospital for Children is conducting a Research Study for children and adolescents aged  5 - 17 years old who have Autism.  If your  5 - 17 year old has Autism, he or she may qualify for a research study involving study medication and clinic visits with a child psychiatrist and qualified research staff at no charge.  The purpose of this study is to find out if the medication, aripiprazole, is helpful for the treatment of irritability, aggression and/or self injurious behavior as well as to determine if adding the medication, D-cycloserine, improves social behavior in children and adolescents with autism. 

For more information about this study, click here.

In addition to free medication, some subjects may be able to participate in functional magnetic resonance imaging (fMRI) research designed to study brain activity.

Participation requirements and risks involved in this study will be disclosed prior to study enrollment.  If you are interested in participating or would like more information, please call our research staff at: (317) 948-9766.

For more information about this study, click here.

TARGETED PHARMACOLOGICAL INTERVENTIONS FOR AUTISM:  A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATOMOXETINE IN CHILDREN AND ADOLESCENTS WITH AUTISM

The Christian Sarkine Autism Treatment Center at Riley Hospital for Children is conducting a research study for children and adolescents ages 5 - 15 who have autistic disorder, Asperger's disorder, or pervasive developmental disorder, not otherwise specified and who also have symptoms such as: overactivity, impulsivity, and/or inattention.  The study involves a non-stimulant medication and clinic visits at no charge.  If you would like to find out more about this research study at Riley Hospital for Children, please contact us at (317) 948-9766 or at kidpsych@iupui.edu.

For more information about this study, click here.

AN OPEN-LABEL (PART ONE) AND A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED (PART TWO) STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF MEMANTINE IN PEDIATRIC PATIENTS WITH AUTISM, ASPERGER'S DISORDER OR PDD.

The Christian Sarkine Autism Treatment Center at Riley Hospital for Children is conducting a research study for 6-12 year old children with Autism, Asperger's Disorder and PDD.  If your 6-12 year old c hild has Autism, Asperger's Disorder, or PDD he or she may qualify for a research study involving an investigational study medication and clinic visits with a c hild psychiatrist and qualified research staff at no charge.  This 15-week study, conducted by Dr. David J. Posey, of the Indiana University School of Medicine is looking at the use of the medication memantine, as a treatment for improving the core symptoms of autism.  Benefits of the study include:  improvements of symptoms of autism, medical asessments and study drug provided at no charge.  Risks include:  discomfort associated with blood draws, being assigned to placebo or side effects from study medication.  Participation requirements plust additional benefits and risks involved in this study will be disclosed prior to study enrollment.  If you are interested in participating or would like more information, please contact the Christian Sarkine Autism Treatment Center at (317) 948-9766 or kidpsych@iupui.edu

 

Fragile X Syndrome


FRAGILE X SYNDROME RESEARCH STUDY

Craig Erickson, M.D. of The Section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a study designed to study the effects of acamprosate in individuals with Fragile X syndrome.  Participants must be adults between the ages of 18 and 50 with Fragile X syndrome.  Participants will receive study medication at no charge.  This study will also evaluate a certain protein in the blood in people with Fragile X Syndrome and Autism Spectrum Disorders. This study is also looking for adults between the ages of 18 and 50 with an Autism Spectrum Disorder who are not taking acamprosate.  

For additional information about study requirements and study procedures, please contact one of Dr. Craig Erickson’s research staff at (317) 948-9766 or kidpsych@iupui.edu.

FRAGILE X RESEARCH STUDY

The Section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a study designed to study the effects of acamprosate in individuals with Fragile X syndrome. Participants must be children between the ages of 5 and 17 with Fragile X syndrome. Participants will receive study medication at no charge.

For additional information about study requirements and study procedures, please call one of Dr. Craig Erickson's research staff at (317) 948- 9766. 

RO4917523 AND FRAGILE X SYNDROME

The Indiana University School of Medicine is conducting research designed to study the safety and tolerability of an investigational drug, RO4917523 in individuals with fragile X syndrome. Participants must be adults between the ages of 18 and 50 with fragile X syndrome. Participants must not have a major medical illness or severe self-injurious behavior. Participants will receive study medication at no charge.

If you would like to find out more about this research study conducted by Craig Erickson, M.D. of the Fragile X Research and Treatment Center at Riley Hospital, please contact a member of the research team at (317) 948-9766 or at kidpsych@iupui.edu.

THE NEUROBEHAVIORAL PHENOTYPE OF FRAGILE X SYNDROME

The Child & Adolescent Psychiatry Fragile X Syndrome Clinic at Riley Hospital for Children is conducting a Research Study for individuals age 3 and older with Fragile X Syndrome. Your 3 year or older child with Fragile X Syndrome may qualify for this study involving psychological testing & structured surveys designed to describe behaviors & mental illnesses common to Fragile X Syndrome. Participation requirements and risks involved in this study will be disclosed prior to study enrollment. If you are interested in participating or would like more information, please contact us at (317) 948-9766.

For more information about this study, click here.

 

OUR RESEARCH PHONE NUMBER HAS CHANGED. PLEASE CONTACT 317-944-9766 FOR ALL RESEARCH OPPORTUNITIES.